Premature mortality in active convulsive epilepsy in rural Kenya: causes and associated factors.

OBJECTIVE: We estimated premature mortality and identified causes of death and associated factors in people with active convulsive epilepsy (ACE) in rural Kenya. METHODS: In this prospective population-based study, people with ACE were identified in a cross-sectional survey and followed up regularly...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Ngugi, A, Bottomley, C, Fegan, G, Chengo, E, Odhiambo, R, Bauni, E, Neville, B, Kleinschmidt, I, Sander, J, Newton, C
Materiálatiipa: Journal article
Giella:English
Almmustuhtton: Lippincott Williams and Wilkins 2014
Govvádus
Čoahkkáigeassu:OBJECTIVE: We estimated premature mortality and identified causes of death and associated factors in people with active convulsive epilepsy (ACE) in rural Kenya. METHODS: In this prospective population-based study, people with ACE were identified in a cross-sectional survey and followed up regularly for 3 years, during which information on deaths and associated factors was collected. We used a validated verbal autopsy tool to establish putative causes of death. Age-specific rate ratios and standardized mortality ratios were estimated. Poisson regression was used to identify mortality risk factors. RESULTS: There were 61 deaths among 754 people with ACE, yielding a rate of 33.3/1,000 persons/year. Overall standardized mortality ratio was 6.5. Mortality was higher across all ACE age groups. Nonadherence to antiepileptic drugs (adjusted rate ratio [aRR] 3.37), cognitive impairment (aRR 4.55), and age (50+ years) (rate ratio 4.56) were risk factors for premature mortality. Most deaths (56%) were directly related to epilepsy, with prolonged seizures/possible status epilepticus (38%) most frequently associated with death; some of these may have been due to sudden unexpected death in epilepsy (SUDEP). Possible SUDEP was the likely cause in another 7%. CONCLUSION: Mortality in people with ACE was more than 6-fold greater than expected. This may be reduced by improving treatment adherence and prompt management of prolonged seizures and supporting those with cognitive impairment.